Development Center for Biotechnology

Dcb-USA LLC

Chu-Bin Liao

Shao-Zheng Peng

Shih-Chieh Yen

Mann-Yan Kuo

Szu-Liang Lai

Yu-Chih Pan

Chen-Hsuan Ho

Hung-Jyun Huang

Shian-Yi Chiou

Nan-Horng Lin

Yu-Kai Chen

Chun-Chung Lee

Po-Ting Chen

Hui-Chen Wang

Hung-Kai Chen

Jiann-Jyh Huang

Chih-Yung Hu

Chen-Wei Huang

Paonien Chen

Pao-Nien Chen

Yuan-Ting Cho

Yen-Yu Wu

Tsung-Hui Li

Chao-Cheng Chiang

Bo-Rong Chen

Sih-Yu Chen

Ya-Ting Juan

Yi-Mei Chang

Huei-Ru Yang

Yuan-Chun Liao

Yu-Hsun Lo

Tze-Ping Yang

Wen-Bin Ke

Chen-Jei Hong

Kao-Jean Huang

A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and/or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and/or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and/or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

Heterocyclic pyrazole derivatives as type III receptor tyrosine kinase inhibitors

The present invention relates to a novel antibody, an antigen-binding fragment thereof and the uses of the antibody and fragment, wherein the antibody and the fragment comprise specific complementarity-determining regions (CDRs) and/or specifically bind to human CD73 at specific epitopes.

Anti-CD73 antibodies and use thereof

An antibody, or an antigen-binding fragment thereof, that binds specifically to human CSF-1R includes a heavy chain variable domain that contains a HCDR1 region having the sequence of SEQ ID NO: 4, a HCDR2 region having the sequence of SEQ ID NO: 5, and a HCDR3 region having the sequence of SEQ ID NO: 6; and a light chain variable domain that contains a LCDR1 region having the sequence of SEQ ID NO: 7, a LCDR2 region having the sequence of SEQ ID NO: 8, and a LCDR3 region having the sequence of SEQ ID NO: 9. The heavy chain variable domain comprises the sequence of SEQ ID NO: 2, and wherein the light chain variable domain comprises the sequence of SEQ ID NO: 3.

Anti-human CSF-1R antibody and uses thereof

Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: in which each of variables R, ring A, L, W, V, and G is defined herein. Also disclosed are a method for treating disease or disorder mediated by Tyro3, Axl, and/or Mer kinase with a compound of formula (I) or a tautomer, stereoisomer, isotopologue, or salt thereof and a pharmaceutical composition containing same.

Heterocycle compounds as Tyro3, Axl and MerTK (TAM) family of receptor tyrosine kinase inhibitors

A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NRor O; R, R, R, R, R, Rand Rare defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Quinoxaline compounds, method for preparing the same and use thereof

A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.

Quinoxaline compounds as type III receptor tyrosine kinase inhibitors

A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; Lis &#x2014;N(R)&#x2014;, &#x2014;O&#x2014;, &#x2014;C(S)&#x2014;, &#x2014;C(O)&#x2014;, or &#x2014;S&#x2014;; Lis &#x2014;N(R)&#x2014; or &#x2014;O&#x2014;; Rand Rare independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C-Calkoxy, C-Calkoxy C-Calkoxy, N,N&#x2014;(C-Cdialkyl)amino C-Calkoxy, N&#x2014;(C-Calkyl)amino C-Calkoxy, C-Calkanoyl, C-Calkanoyloxy, N&#x2014;(C-Calkyl)amino, N,N&#x2014;(C-Cdialkyl)amino, C-Calkanoyl amino, or heterocyclyl, wherein C-Calkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R, Rand Rare independently hydrogen, fluorine or chlorine; Ris C-Calkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or Rand Rform a 5-6 membered cyclyl or heterocyclyl.

Quinazoline compounds, method for preparing the same and use thereof

The present invention relates to a compound of formula (I): or hydrates, solvates, prodrugs, or pharmaceutically acceptable salts thereof, wherein R, R, X, Y, ring A, Rand Rare as defined in the detailed description and claims. The compound of formula (I) are receptor tyrosine kinase (RTK) inhibitors and have efficacy for the treatment, prevention, or amelioration of RTK-related diseases.

Heterocyclic pyrazole compounds, method for preparing the same and use thereof

A compound for treating protein kinase-related disease or disorder having a structure of formula (A): wherein X is N or CH; Y is NH, O, or CH; Z is an aryl or a heteroaryl; and R, R, R, and Rare independently H, halo, nitro, cyano, aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, &#x2014;OR, &#x2014;C(O)R, &#x2014;C(O)NRR, &#x2014;NRC(O)R, &#x2014;NRR, &#x2014;S(O)R, &#x2014;S(O)NRR, &#x2014;NRS(O)R, &#x2014;N&#x2550;CRR, or &#x2014;NRC(O)NHR, wherein each of Rand R, independently, is H, alkyl, alkenyl, alkynyl, aryl, aryloxy, alkoxy, hydroxy, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl, or Rand R, together with the nitrogen atom to which they are bonded, form heteroaryl, heterocycloalkyl, or heterocycloalkenyl; or Rand Rare as defined above, and Rand Rtogether with the carbons, to which they are attached, form a heterocycloalkenyl or heteroaryl.

Quinazoline compounds as kinase inhibitors

Growing community of inventors

Taipei, Taiwan

Chu-Bin Liao